Last updated: February 27, 2026
What is NDC 71930-0047?
National Drug Code (NDC) 71930-0047 refers to Bravecto (fluralaner) topical solution for dogs. Bravecto is an antiparasitic medication used primarily for the prevention of fleas and ticks in canines. It is manufactured by Merck (now Merck Animal Health).
Market Overview
Product Positioning
Bravecto has gained substantial market share since its approval by the FDA in 2014, considered a leading topical treatment in the canine parasite prevention segment. It offers a three-month duration of protection, reducing the frequency of administration compared to monthly treatments.
Market Players
Key competitors include:
- Simparica (sarolaner), Zoetis
- Seresto (imidacloprid and flumethrin), Elanco
- NexGard (afoxolaner), Merial/Zoetis
- Activyl (indoxacarb), Merck
Market Size
In 2022, the U.S. veterinary antiparasitic market was valued at approximately $1.2 billion, with flea and tick products accounting for roughly $600 million. Bravecto held around 45-50% of this segment, indicating annual sales near $270-300 million.
Unit Sales Trends
Between 2018 and 2022, Bravecto's U.S. unit sales increased at a Compound Annual Growth Rate (CAGR) of approximately 8%. The growth was driven by expanding pet ownership, increased veterinary visits, and consumer preference for long-acting formulations.
Regulatory Status
Bravecto Topical for dogs has been approved and marketed globally, with regulatory variations impacting access. The U.S. continues as its primary market with stable regulatory approval status.
Revenue and Price Trends
Historical Pricing
Average retail prices for Bravecto topical vary based on dog weight, ranging from approximately $50 to $80 per treatment. The price per dose has remained relatively stable over recent years with minor fluctuations due to market competition.
Pricing Dynamics
- Per Dose Price: Typically between $50 and $80
- Price per Chew (oral): Slightly higher, reflecting different dosage forms
- Discounting and Rebates: Pharmaceutical companies often offer rebates to veterinarians and distributors, affecting net sales figures
Price Comparisons with Competitors
| Product |
Formulation |
Price Range (per dose) |
Duration |
Market Share (2022) |
| Bravecto |
Topical |
$50 - $80 |
3 months |
~50% |
| Simparica |
Chewables |
$45 - $70 |
1 month |
~20% |
| Seresto |
Collar |
$70 - $90 (per collar) |
8 months |
~15% |
| NexGard |
Chewables |
$50 - $75 |
1 month |
~10% |
Price Projections (Next 3-5 Years)
Factors Influencing Price
- Market Saturation: As Bravecto approaches full penetration, price stability is expected.
- Competitive Pressure: Introduction of new products or formulations can drive price reductions.
- Regulatory Changes: Measures affecting drug approval or reimbursement may influence prices.
- Manufacturing Costs: Prices of active ingredients and raw materials impact wholesale and retail pricing.
Projected Price Trends
| Year |
Estimated Price Range (per dose) |
Notes |
| 2023 |
$50 - $85 |
Stable, with minor fluctuations |
| 2024 |
$50 - $85 |
Market equilibrium maintained |
| 2025 |
$50 - $80 |
Slight downward pressure from increased competition |
| 2026 |
$50 - $80 |
Continued stabilization |
Revenue Outlook
Assuming stable unit sales nearing 2.7 million doses annually in North America, total gross sales could reach approximately $135-$200 million annually by 2026, factoring in price ranges.
Risks and Opportunities
Risks
- Entry of new competitors offering long-acting formulations at lower prices
- Regulatory shifts affecting formulation approval or reimbursement
- Potential patent expirations, although Bravecto's patent life extends beyond 2025
Opportunities
- Expansion into emerging markets with high pet ownership growth
- Development of combination products for multi-parasitic coverage
- Digital marketing and veterinary education to increase adoption
Key Takeaways
- Bravecto’s market share stabilizes at around 50% with consistent sales growth driven by its long-acting formulation.
- Price stability persists due to brand loyalty and market positioning; minor declines may occur with increased competition.
- Revenue projections estimate annual sales between $135 million and $200 million by 2026, assuming steady volume and pricing.
FAQs
Q1: How does the price of NDC 71930-0047 compare internationally?
Prices vary significantly across countries, often influenced by reimbursement policies, import taxes, and market competition. European prices average around 40-60 euros per dose, comparable to U.S. pricing after exchange adjustments.
Q2: Are there patent protections that influence pricing?
Yes, patents protect Bravecto until at least 2025 in key markets, allowing for limited generic competition.
Q3: What is the impact of new product approvals on the market?
New long-acting formulations or combination therapies could pressure prices downward, especially if priced more competitively.
Q4: How does veterinary-prescribed pricing affect consumer prices?
Rebates, discounts, and out-of-pocket costs vary, impacting the actual price consumers pay. Wholesale and veterinary practice margins influence final retail pricing.
Q5: Is there potential for price increases due to raw material costs?
Possible if active ingredient costs rise or supply chain disruptions occur, although current raw material prices for fluralaner remain stable.
References
- American Veterinary Medical Association. (2022). U.S. pet industry market analysis.
- Pfizer Animal Health. (2014). Bravecto (fluralaner) prescribing information.
- Packaged Facts. (2022). Pet Market Overview.
- Statista. (2023). Veterinary pharmaceuticals market size and forecast.
- U.S. Food and Drug Administration. (2022). Approved Animal Drugs.
